stockrow
Friday 6 November 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
103.93
19.03
−15.48%
Follow HALO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.79 | 22.13 | 22.24 | 26.29 |
P/S ratio |
5.77 | 5.06 | 5.52 | 6.97 | |
P/FCF ratio |
12.51 | 11.44 | 11.39 | 14.18 | |
P/Operating CF |
36.82 | 42.40 | 38.10 | 48.64 | |
P/B ratio |
165.22 | 34.77 | 63.95 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.72 | 6.27 | 6.67 | 8.18 | |
EV/EBITDA |
19.20 | 15.27 | 15.43 | 20.49 | |
EV/Operating CF |
16.54 | 13.97 | 13.55 | 16.41 | |
EV/FCF |
16.72 | 14.17 | 13.76 | 16.64 | |
Quick Ratio |
3.30 | 2.14 | 1.99 | 3.36 | |
Current Ratio |
4.66 | 2.76 | 2.71 | 3.88 | |
Net Debt/EBITDA |
(31.07) | 8.28 | 5.93 | 0.00 | |
Debt/Assets |
84.85% | 80.24% | 83.29% | 93.58% | |
Debt/Equity |
43.89 | 9.76 | 14.95 | (58.84) | |
Asset Turnover |
0.61 | 0.62 | 0.72 | 0.63 | |
Operating CF/Net income |
(1.55) | 1.20 | 1.05 | 1.05 | |
Capex/Depreciation |
(15.78) | (0.10) | (0.12) | — | |
Interest Coverage |
(18.91) | 33.50 | 51.48 | 48.80 | |
Research and Development Expense of Revenue |
70.12% | 6.79% | 5.75% | 5.63% | |
Selling, General and Administrative Expense of Revenue |
17.05% | 15.36% | 11.85% | 11.81% | |
Intangible Assets out of Total Assets |
0.62 | 0.57 | 0.58 | 0.42 | |
Share Based Compensation of Revenue |
3.67% | 4.42% | 3.68% | 3.41% | |
Graham Net Nets |
(0.20) | (0.19) | (0.16) | (0.13) | |
Graham Number |
4.89 | 11.05 | 9.85 | 0.00 | |
Earnings Yield |
3.88% | 4.52% | 4.50% | 3.80% | |
Free Cash Flow Yield |
7.99% | 8.74% | 8.78% | 7.05% | |
Revenue per Share |
3.77 | 3.19 | 4.10 | 4.33 | |
Operating CF per Share |
1.83 | 1.52 | 2.05 | 2.27 | |
Capex per Share |
(3.76) | (0.03) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(1.93) | 1.49 | 2.02 | 2.27 | |
Cash per Share |
1.19 | 2.70 | 1.97 | 9.44 | |
Shareholders Equity per Share |
0.41 | 1.86 | 1.22 | (0.49) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.41 | 1.86 | 1.22 | (0.49) | |
Free Cash Flow |
(231.27) | 176.34 | 236.72 | 258.27 | |
Working Capital |
648.12 | 639.83 | 588.59 | 1,370.64 | |
Capital Expenditures |
(450.30) | (3.74) | (4.17) | — | |
Net Current Asset Value |
(1,651.30) | (1,450.05) | (1,500.84) | (1,681.85) | |
EV/EBIT |
22.98 | 18.48 | 18.58 | 21.86 | |
Capex to Sales |
1.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
17.20 | 14.91 | 15.37 | 18.63 | |
| Other line items | |||||
Average Receivables |
374.86 | 381.31 | 386.08 | 435.81 | |
Average Payables |
15.57 | 17.09 | 21.15 | 24.45 | |
Average Inventory |
159.17 | 160.17 | 159.32 | 159.20 | |
Average Assets |
2,294.40 | 2,434.63 | 2,315.65 | 2,847.29 | |
Average Common Equity |
206.32 | 350.95 | 238.15 | 224.34 |
Columns are period end dates · fundamentals updated 5 Nov 2026